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Abstract
Background: Although enzyme replacement therapy (ERT) is available for several lysosomal storage disorders, the benefit of
this treatment to the skeletal system is very limited. Our previous work has shown the importance of the Toll-like receptor 4/
TNF-alpha inflammatory pathway in the skeletal pathology of the mucopolysaccharidoses (MPS), and we therefore
undertook a study to examine the additive benefit of combining anti-TNF-alpha therapy with ERT in a rat model of MPS type
VI.
Methodology/Principal Findings: MPS VI rats were treated for 8 months with NaglazymeH (recombinant human N-acetyl-
galactosamine-4-sulfatase), or by a combined protocol using NaglazymeH and the rat-specific anti-TNF-alpha drug,
CNTO1081. Both protocols led to markedly reduced serum levels of TNF-alpha and RANKL, although only the combined
treatment reduced TNF-alpha in the articular cartilage. Analysis of cultured articular chondrocytes showed that the
combination therapy also restored collagen IIA1 expression, and reduced expression of the apoptotic marker, PARP. Motor
activity and mobility were improved by ERT, and these were significantly enhanced by combination treatment. Tracheal
deformities in the MPS VI animals were only improved by combination therapy, and there was a modest improvement in
bone length. Ceramide levels in the trachea also were markedly reduced. MicroCT analysis did not demonstrate any
significant positive effects on bone microarchitecture from either treatment, nor was there histological improvement in the
bone growth plates.
Conclusions/Significance: The results demonstrate that combining ERT with anti-TNF- alpha therapy improved the
treatment outcome and led to significant clinical benefit. They also further validate the usefulness of TNF-alpha, RANKL and
other inflammatory molecules as biomarkers for the MPS disorders. Further evaluation of this combination approach in
other MPS animal models and patients is warranted.
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Introduction
The mucopolysaccharidoses (MPS) are a group of 11 distinct
enzyme deficiencies that result in defective catabolism of
glycosaminoglycans (GAGs) [1]. Due to these inherited enzyme
defects, GAGs progressively accumulate in lysosomes and other
intracellular compartments of MPS patients, as well as in
extracellular connective tissue matrices. As expected, the major
clinical consequences of these enzyme deficiencies are most
evident in connective tissue organs, including cartilage, skin and
bone. Major clinical features include a course and abnormal facial
appearance and cranial development, short limbs, degenerative
joint disease, trachea and heart valve defects, and in some cases
neurological involvement.
Several approaches have been evaluated for the treatment of
these diseases, including bone marrow transplantation (BMT) and
enzyme replacement therapy (ERT). BMT has proven effective to
varying degrees, but has limited effects on the bones and joints [2].
It also is impeded by the deleterious side effects of immunosup-
pressive and myeloablative medications, and the occurrence of
graft versus host disease. The use of cord blood has partially
mitigated these complicating factors, although they often remain
significant. ERT involves the intravenous infusion of recombinant
enzymes, usually weekly or biweekly [2]. In large part, the
effectiveness of this therapy relies on the biodistribution of the
infused enzymes, which are readily delivered to the reticuloendo-
thelial organs (e.g., liver, spleen), but less so to other organs. For
the MPS disorders, ERT is available for three types: MPS I
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and MPS VI (Maroteaux-Lamy Syndrome) [7,8,9]. Significant
quality-of-life improvements have been noted following ERT,
including improved mobility, breathing, and joint flexibility.
However, there is little or no evidence that ERT directly impacts
the cartilage and bone disease in MPS patients, and these positive
clinical effects are therefore thought to derive mostly from soft
tissue changes (e.g., tendons). Other experimental therapies are
also under evaluation for the MPS disorders, including gene
therapies [10,11] and the use of recombinant enzymes fused to
cell-specific targeting sequences [12,13].
For the past several years our laboratory has been investigating
the joint and bone pathology in MPS animal models, with the
long-term goal of developing improved therapies, alone or in
conjunction with ERT, BMT, or gene therapy [14,15,16]. As part
of this ongoing research, we have identified a number of
abnormalities in MPS animal models, including enhanced death
(apoptosis) of MPS articular chondrocytes, excessive proliferation
of MPS synovial fibroblasts, and disorganization of MPS growth
plates. We have also found that the addition of GAGs to the
culture media of normal articular chondrocytes induced apoptosis
and the release of inflammatory markers, suggesting that GAG
storage itself may be an initiating, pro-inflammatory event in the
MPS disorders [17]. GAG storage in MPS cells also led to
activation of the Toll-like receptor 4 (TLR4) signaling pathway,
resulting in the release of TNF-alpha and other inflammatory
cytokines.
We therefore bred MPS mice (MPS VII, Sly disease) to TLR4
knock-out mice, and found that the double knock-out MPS
animals had markedly reduced TNF-alpha, IL1-beta, RANKL
and other cytokines, improved bone growth and more organized
bone growth plates, and reduced chondrocyte cell death [18]. This
led us to conduct a preliminary analysis of anti-TNF-alpha therapy
in MPS VI rats using RemicadeH, the FDA-approved anti-human
TNF-alpha monoclonal antibody used in arthritis and other
inflammatory diseases [19]. In this study we found that anti-TNF-
alpha treatment reduced the levels of inflammatory cytokines in
MPS VI animals, and also reduced the number of apoptotic
articular chondrocytes. However, there was no effect on bone
growth or clinical improvements in motor activity.
In the current study we have extended these findings and
evaluated a combined ERT/anti-TNF-alpha approach in the
MPS VI rats. We found that this combined approach provided
several benefits over ERT alone. These included improved gait
and motor activity, thinner, less deformed tracheas, and
moderately longer bones. Collagen IIA1 expression also was
restored in the articular cartilage, and apoptosis was reduced.
Materials and Methods
Animals
The MPS VI rats have been previously described and used
extensively by our group and others [20,21]. A breeding colony
was established from heterozygous mating pairs, and genotyping
was performed on tail clip DNA using established methods [21].
Euthanasia of rats was performed using carbon dioxide inhalation.
All animal protocols were approved by the Mount Sinai
Institutional Animal Care and Use Committee (permit # 08-
0108), and were performed in accordance with NIH guidelines.
Treatment of MPS VI Rats
NaglazymeH (recombinant human N-acetylgalactosamine-4-
sulfatase) was obtained from the BioMarin Pharmaceutical Inc.,
and CNTO1081 was from Centocor Ortho Biotech Inc. Twenty
one-day-old (pre-symptomatic) MPS VI rats were divided into two
groups (n=8/group), and subjected to either ERT or combined
ERT/anti-TNF-alpha therapy. Animals receiving ERT alone
were injected i.v. (tail vein) weekly with 1 mg/kg of NaglazymeH.
Those receiving combined therapy also were injected i.v. with
3 mg/kg of CNTO10181 twice per week (every third day).
Treatment was carried out for a total of 32 weeks. Serum was
collected every 2 weeks for TNF-alpha and RANKL analysis (see
below). For each group, the treated animals were sacrificed 2
weeks after the last injection (37 weeks of age). Age-matched
normal and untreated MPS VI rats were used as controls
throughout the study.
Tracheas, femora, and tibias were collected from the control
and treated MPS VI rats, and placed in either phosphate buffered
saline for the isolation of fibroblast-like synoviocytes (FLS) and
articular chondrocytes, or fixed in neutral buffered 10% formalin
(Sigma Chemical) for histology, microCT analysis, and immuno-
histochemistry (see below). The fixed bones were decalcified in 8%
formic acid (Sigma Chemical) for 5 days, paraffin embedded, and
sectioned (5 mm) for subsequent staining. Primary FLS and
articular chondrocyte cultures were established as previously
described [16,17], and expression of inflammatory and apoptosis
markers were assessed by western blotting.
MicroCT Image Acquisition
Three-dimensional images of the 37-week-old femora from age-
matched normal, untreated and treated MPS VI rats were
obtained using the eXplore Locus SP PreClinical Specimen
microCT system (GE Healthcare; London, Ontario, Canada).
Scans were performed at a voxel size of 14.4 mm. The scan
protocol consisted of 3600 image acquisitions over a five hour scan
(acquisition parameters: 80 kVp, 80 uA, 3 second exposure time
[,69 kJ], 0.0100 aluminum beam filter). A calibration phantom
containing air, water, and hydroxyapatite (SB3: Gamex RMI,
Middleton, WI, USA) was included in all scans to adjust for the
variability in X-ray attenuation inherent to independent scan
sessions.
Bone Length and Trachea Measurements
Limb and trachea measurements were taken at the end of the
study (37 weeks of age). The length of each femur was measured
from the microCT images using the Microview software. The
greater trochanter was used as the proximal margin of the femur,
whereas the extent of the distal condyles was considered the distal
margin. Thus, the length of each femur was computed roughly
along the vertical axis of the bone. For validation, the physical
femora and tibia lengths, as well as the width of the tracheas, was
measured with a digital caliper. The mean of the two treatment
groups (ERT and combined ERT/CNTO1081) were compared
using standard student t test analysis.
Cortical Bone Analysis
A representative mid-diaphyseal region of each femoral
microCT image was isolated for analysis. The volume of interest
(VOI) was limited proximally by the initial appearance of the third
trochanter and distally by the appearance of the metaphysis,
indicated by trabecular bone formation and shaft width expansion.
The analysis region was not restricted by measured size to
accommodate variances in bone length. Cortical bone was
manually segmented from residual trabecular bone and thre-
sholded independently to differentiate bone and non-bone voxels.
The MicroView software was employed to quantify morphological
traits.
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tissue mineral density (TMD) of cortical bone within each sample.
TMD represents the average mineral value of the bone voxels
only, expressed in hydroxyapatite (HA) density equivalents, in
contrast to the bone mineral density (BMD), which includes non-
bone voxels. TMD was calculated by converting the gray-scale
values of bone voxels from Hounsfield units (HU) to mineral values
(mg/cc of HA) through the use of a calibration phantom
containing air, water, and HA (Gamex RMI, Middleton, WI,
USA). TMD is defined as the average bone voxel HU value
divided by the average HU value of the HA phantom multiplied
by 1130 mg/cc (density of HA)
2.
Trabecular Bone Analysis
Trabecular VOIs were extracted from a 4 mm region of the
distal metaphysis of the femur using the MicroView image
processing software. The distal margin was defined as the initial
appearance of the physis. In lieu of an obvious proximal landmark,
a standard distance (4 mm) was selected to encompass the
trabecular VOI. Trabecular bone was segmented from the cortical
bone in serial axial slices to generate a three dimensional
representation of the trabecular VOI. Each trabecular VOI was
thresholded to distinguish bone from non-bone voxels. The TMD
of trabecular bone was computed from the microCT scan in the
same fashion as for cortical bone, with the inclusion of the same
calibration phantom in each scan. Microarchitectural traits were
measured using the Microview software, including trabecular bone
volume fraction, trabecular bone surface-to-volume ratio, and
trabecular number, thickness, and spacing. All values were
averaged across the entire VOI.
Locomotor Function
Age-matched 37-week-old normal and untreated MPS VI and
treated MPS VI rats were placed on an accelerating Rotarod series
8 (IITC Life Science) for evaluation as described previously [22].
Animals were primed on the rod for two consecutive days prior to
the actual recording. The rotarod was set at increasing speeds
from 10 to 30 rpm over 3 minutes, and an average of the latency
to fall off from the rod was recorded. Results were analyzed by
one-way analysis of variance (ANOVA) with the variable group.
Motility Analysis
The fore and hind paws of treated and control animals were
stained with two different colors using non-toxic dye. The rats
were trained to walk through a tunnel for two consecutive days,
leaving their paw prints on blotting paper. On the third day
several parameters were measured; distance between the left and
right front paws in the longitudinal direction, the angle that was
formed, and the distance between the front and hind right paws.
For statistical analysis, group differences were assessed using
multivariate analyses of variance (MANOVAs), followed by post
hoc Bonferroni adjustments for all time points tested.
Articular Cartilage, Synovium and Growth Plate Histology
and Immunohistochemistry
Femora from 37-week-old normal, untreated MPS VI and
treated MPS VI rats were fixed, embedded, sectioned, and stained
with toluidine blue and H & E. Immunohistochemical studies were
performed as well. For immunohistochemistry, sections were fixed
with 4% paraformaldehyde/PBS, permeabilized with 0.5%
Triton-X-100, blocked, and incubated overnight at 4uC with
primary rabbit polyclonal anti-mouse collagen type IIA1 (rabbit
polyclonal sc-28887, Santa Cruz Biotechnology) and TNF-alpha
antibody (goat polyclonal sc-1348, Santa Cruz Biotechnology).
After several rinses with PBS, visualization was accomplished using
a fluorescent secondary antibody, donkey anti-goat IgG-Cy-3
(711-165-152, Jackson Laboratory). Nuclei were stained with
1 mg/ml bis-benzimide Hoechst dye (Sigma-Aldrich) for 10 min,
rinsed, and sections were mounted with an anti-bleaching
mounting media. Slides were visualized and photographed with
a confocal laser-scanning microscope (Carl Zeiss 510 Meta).
Trachea Immunohistochemistry
Tracheas from 37-week-old normal, untreated MPS VI and
treated MPS VI rats were fixed, embedded, sectioned and
prepared as described above. Sections were incubated overnight
with primary mouse monoclonal anti-ceramide antibody
(MID15B4, alexis Corporation) and visualization was accom-
plished using a fluorescent secondary antibody, donkey anti-goat
IgG-Cy-3 (711-165-152, Jackson Laboratory). Slides were visual-
ized and photographed with a confocal laser-scanning microscope
(Carl Zeiss 510 Meta).
Immunoblot Analysis
Articular chondrocytes from 37-week-old normal, untreated
and treated MPS VI rats were collected using sequential enzyme
digestion of cartilage, pelleted and lysed for immunoblot analysis
as previously described [17]. The membranes were incubated with
rabbit polyclonal anti-collagen type IIA1 (sc-8784-R, Santa Cruz
Biotechnology), rabbit polyclonal anti-collagen type X (AB58632,
Abcam), rabbit polyclonal anti-ADAMTS5 (sc-28887, Santa Cruz
Biotechnology), rabbit polyclonal anti-PARP (sc-7150, Santa Cruz
Biotechnology), and rabbit polyclonal anti-GAPDH (sc-25778,
Santa Cruz Biotechnology), as a loading control. The bound
antibodies were recognized by secondary antibodies conjugated to
HRP (NA934V), GE Healthcare). Detection of the antibody
complexes was accomplished using an enhanced chemilumines-
cence detection reagent (Amersham Biosciences).
Serum Immunoassays
Serum TNF-alpha and RANKL in age-matched normal,
untreated and treated MPS VI rats were assessed by immunoas-
says using rat ultrasensitive Biosource Elisa kits (Invitrogen and
ALPCO Diagnostics) according to the manufacturers’ protocols.
All assays were performed in triplicate.
Data Presentation and Statistical Analyses
All experiments were independently replicated at least three
times. The data between two groups were subjected to student’s t-
test analysis, one-way analysis of variance (ANOVA) with the
variable group, multivariate analyses of variance (MANOVAs)
followed by post hoc Bonferroni adjustments. The results were
considered significant at P,0.05. Statistics were performed using
Sigma Stat 3.1 (Systat Software). Graphs represent the mean +/2
standard error of the mean (SEM) of combined data from the
triplicate experiments.
Results
Twenty one-day-old MPS VI rats were treated by either ERT
(1 mg/kg once per week), or by a combined protocol of ERT and
anti-TNF-alpha therapy (3 mg/kg, twice per week). Both were
administered intravenously (tail vein). The animals were treated
for a total of 8 months (i.e., 32 doses of ERT and 64 doses of anti-
TNF-alpha). As controls, normal and untreated MPS VI
littermates were used (n=8 per group). Anti-TNF-alpha therapy
was carried out using a rat-specific monoclonal antibody against
Inflammation & Mucopolysaccharidosis Type VI
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BioMarin) is the human form of recombinant N-acetylgalactosa-
mine-4-sulfatase, the enzyme deficient in MPS VI, and was used
for ERT. The animals were sacrificed 2 weeks after the final
treatment (i.e., 37 weeks-of-age).
Figure 1A summarizes the serum levels of TNF-alpha and
RANKL at the end of the study. Both inflammatory markers were
highly elevated in untreated MPS VI rats as compared to normal
animals, and both treatment protocols led to significant reductions.
The effects were slightly enhanced in the combined treatment
group, although not statistically different. Figure 1B shows
immunohistochemical staining of articular cartilage for TNF-
alpha. Untreated MPS VI animals had elevated cartilage TNF-
alpha, which was modestly reduced by ERT and more so by
combined treatment. Figure 1C shows cross sectional images of
the knees from control and treated MPS VI rats. The synovial
membranes (*) were hyperplastic in untreated MPS VI rats,
leading to the formation of synovial villi (SV). ERT did not reduce
the synovial inflammation, in contrast to combined treatment
where the inflammation and formation of villi was markedly
reduced. Note that storage was still clearly evident in the articular
cartilage (AC) from both treatment groups, as well as in the
subchondral bone (SB). The bold arrowhead in the ERT image
indicates the invasion of the synovial membrane into the SB,
indicative of inflammation.
The effects of these treatments on motor activity and gait also
were evaluated. On an accelerating rotarod apparatus (Figure 2A),
both the ERT and combined treatment animals remained on the
rotating bar for the maximum time (180 seconds) at the lowest
speed (10 RPM), in contrast to untreated MPS VI animals (mean
of 70 seconds). At higher speeds (20 and 30 RPM), a significant
improvement in the combined treatment versus ERT group was
observed. Figure 2B shows representative images of the gait
patterns for these animals. Overall, the ERT treated animals
walked faster with longer, more coordinated strides than the
untreated MPS VI animals, and this was improved by combined
therapy. For example, the angle of the hind paw movement
reduced from 60u (untreated MPS VI), to 45u (ERT) to 30u
(combined), and the distance for the front paw improved from
2.8 cm (untreated) to 4.2 cm (ERT) to 5.1 cm (combined).
MicroCT analysis was used to assess the femur and tibia lengths
in the treated and untreated MPS VI, and normal animals. As
shown in Figure 3A, at 37 weeks-of-age the femora of untreated
MPS VI animals were on average only ,77% those of normal
littermates. No improvements were observed in the ERT group,
while in the animals receiving the combined treatment the femora
were ,6% longer (,83% of normal). The tibias of untreated MPS
VI rats were similarly ,74% of normal, and these were improved
,14% by combined therapy, to ,88% of normal. No
improvement was observed in the ERT group. Although these
improvements in bone length from the combined treatment were
consistently observed, they were more prominent in male animals
and did not reach statistical significance when all of the treated
mice (male and female) were grouped together.
Despite these positive effects on bone length, few changes were
evident in the bone microarchitecture for either treatment group.
Figures 3B & 3C show microCT images of the distal femora. In
untreated MPS VI animals the trabecular density within the
metaphyseal bone was reduced, the physeal growth plate was
dysmorphic and disrupted, and the epiphyseal trabeculae were
disorganized relative to the normal femur (Figure 3B). Mild
improvements from the combined treatment was detected.
Quantitative analysis was conducted to further investigate the
morphological changes in trabecular bone of untreated and
treated MPS VI rats. Representative volume of interests (VOIs) of
the distal metaphysis, immediately proximal to the physis, were
gathered and compared across groups. Three-dimensional images
of trabecular structures were generated to ensure only trabecular
bone was included. From each VOI, the TMD (trabecular mineral
density) and BV (bone volume)/TV (trabecular volume) were
extracted. Neither treatment protocol had a statistically relevant
impact on trabecular bone TMD or BV/TV (data not shown).
MicroCT images of the mid-diaphyseal region of the femora
also were collected. Axial cross-sections at the distal appearance of
the third trochanter were extracted and representative samples
juxtaposed for comparison (Figure 3C). On gross inspection,
untreated MPS VI rats exhibited greater subcortical trabecular
infiltration into the marrow space. The apparent increase in
trabecular density was not corroborated by quantitative measures,
although this gross finding was consistent across the range of
samples. No marked reversal of the trabecular growth resulted
from either treatment.
Quantitative measures of cortical bone morphology were
calculated for the mid-diaphyseal VOIs. Values for the mean
cross-sectional cortical area, total area, and TMD of cortical bone
were gathered to illustrate size and mineralization. Cortical area
was 22% (p=0.002) lower in MPS VI rats compared to normal,
without influencing the total area or TMD. As a result, the relative
cortical area was depressed by 15% (p=0.015), representing a
substantial loss of cortical bone thickness in MPS VI rats at no
expense to the total thickness or mineralization of diaphyseal
femoral bone. Of note, femora of rats treated with ERT or
combined treatment exhibited greater cortical area and relative
cortical area, without a significant change in the total area or
TMD. The addition of anti-TNF-alpha therapy did not augment
the positive effect of ERT therapy. Overall, these findings fell short
of statistical significance.
Robustness was calculated as a final measure of femoral
architecture. Defined as the cross-sectional size relative to length,
robustness captures the relationship between horizontal and
vertical growth. MPS VI femurs were found to be more robust
than normal, consistent with their ‘‘short and fat’’ appearance. No
significant improvement was demonstrated with treatment,
although the combined therapy reduced robustness by 5%
(p=0.25), a modest (albeit insignificant) improvement.
Collapsed and thickened tracheas were evident in the untreated
MPS VI rats (Figure 4A), consistent with the tracheal abnormal-
ities observed in MPS patients [23]. Upon gross inspection, a
notable improvement of the tracheas was observed following
combined treatment, but not ERT. Tracheas from untreated MPS
VI rats had a statistically smaller cross-sectional area when
compared to normal (2.960.6 mm
2 versus 7.560.8 mm
2;
p=0.0002). Tracheas from ERT treated animals were modestly,
but significantly, improved (3.660.5 mm
2; p=0.02 compared to
untreated), while in the combined treatment group the cross-
sectional areas were nearly doubled, 6.060.8 mm
2 (p=0.003
compared to untreated).
Ceramide is a signaling sphingolipid that is involved in the
induction of inflammation, apoptosis and infection, and has been
shown to accumulate in MPS articular chondrocytes [18].
Ceramide also accumulates in the trachea from several diseases
with respiratory complications, and plays an important role in
cartilage homeostasis [24], leading us to examine ceramide in the
tracheas of the MPS VI rats. As seen in Figure 4B, strong ceramide
staining was observed in the epithelial cells of untreated and ERT-
treated MPS VI rat tracheas, and was reduced to normal in
tracheas from animals receiving combined treatment.
Inflammation & Mucopolysaccharidosis Type VI
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analysis of the bone growth plates was performed. MPS VI rat
growth plates are thicker than those of wild-type littermates due to
the large, vacuolated cells. In addition, the normal column
organization of the growth plates is disrupted in the MPS animals,
contributing to the abnormal bone formation [18,25]. Neither
treatment protocol had a noticeable effect on the MPS VI growth
plate histology (data not shown).
Finally, articular chondrocytes were collected from treated and
untreated MPS VI animals to assess changes in collagen
expression and apoptosis markers. The levels of collagen IIA1
and X are lower than normal in MPS VI rats, and each was
elevated in the treated versus untreated MPS VI animals
(Figure 5A). As evident in this western blot, combined treatment
led to greater collagen IIA1 expression, a finding that was
confirmed by immunohistological staining in cartilage slices
(Figure 5B). Expression of the matrix-degrading enzyme, aggre-
canase, ADAMTS5, was reduced by both ERT and combined
treatment, while the apoptosis marker, PARP, which is elevated in
chondrocytes from MPS VI rats [15], was only reduced by the
combined treatment protocol.
Discussion
Despite the fact that ERT provides clear clinical benefits to
MPS patients, including improved joint mobility, motility and
breathing [7,26], the effectiveness of this treatment on cartilage
and bone are extremely limited. This may be attributed to the
biodistribution of the infused recombinant enzymes, which cannot
readily reach these tissues due to their poor vascular supply, and
the fact that the target cells (e.g., chondrocytes) are embedded
within a matrix that impedes drug delivery. The improved joint
mobility in MPS patients following ERT is therefore thought to
relate to soft tissue changes (e.g., tendons), rather than direct
effects on cartilage and bone. In addition, even when the
recombinant enzymes have been injected directly into the articular
space of MPS animals at very early ages, the effects on the bone
and cartilage have been very limited [27]. Thus, there remains an
important need to improve the outcome of ERT in these tissues.
Our previous work has demonstrated the importance of the
TLR4 inflammatory pathway in the pathogenesis of cartilage and
bone in MPS animal models [18]. Since no direct TLR4 inhibitors
are approved for clinical use, we evaluated the effectiveness of anti-
TNF-alpha therapy, a downstream product of the TLR4 pathway,
in the rat model of MPS VI. In humans, anti-TNF-alpha
antibodies (e.g., RemicadeH (infliximab)) are used to treatment
several common inflammatory diseases, including rheumatoid
arthritis, psoriatic arthritis and Crohn’s disease [28,29,30]. We
found that treatment of MPS VI rats by this anti-TNF-alpha
therapy reduced inflammation and articular cartilage apoptosis,
but did not significantly improve bone growth or mobility [18].
In the current study the effectiveness of combining ERT with
anti-TNF-alpha therapy was evaluated to determine if there was
any clinical/pathological benefit over ERT alone. We used a rat-
specific monoclonal antibody against TNF-alpha (CNTO1081),
and the human recombinant N-acetyl-galactosamine-4-sulfatase
(NaglazymeH) for ERT. Immune responses against this human
enzyme are known to occur in MPS VI rats and cats after
intravenous injections, although these reactions are generally not
severe. Immunosuppression can be used to minimize this response
[31], but since we were already administering anti-TNF-alpha
therapy in this study, a known immunosuppressant, an additional
complex treatment was not added to our experimental design. It
should be noted that for some ERT therapies immunological
responses to the infused enzymes may seriously limit their
effectiveness, and one potential benefit of combining anti-TNF-
alpha therapy with ERT may be to minimize this response and
avoid the need for additional immunosuppression. However, this
potential benefit must be carefully balanced with the potential risk
of increased infection, and therefore carefully evaluated in
controlled clinical trials.
Interestingly, one of the initial observations from the current
study was that ERT alone substantially reduced the serum levels of
several inflammatory markers, including TNF-alpha and RANKL.
The serum levels of these cytokines reflects the overall inflamma-
tory state of these animals, rather than any specific organ or tissue,
and we hypothesize that the reduction in the circulating levels of
these molecules following ERT was likely due to the effectiveness
of the therapy in organs known to be readily assessable to the
recombinant enzyme (e.g., liver). We have previously shown that
the inflammatory disease in MPS is driven, in large part, by GAG
storage, and a reduction of GAGs in these organs following ERT
may have led to reduced systemic TNF-alpha release [18]. The
fact that the circulating levels of TNF-alpha (and other
inflammatory molecules) was substantially reduced in these
animals following ERT also suggests that this therapy might have
positive, secondary anti-inflammatory effects on other organs that
are not accessible to the enzyme (e.g., cartilage), providing
additional benefit.
We assessed the clinical improvement in the treated MPS VI
animals by two measures of motor activity, performance on an
accelerating rotarod apparatus and gait analysis. ERT improved
these endpoints, but there was a clear, additive benefit of
combining this therapy with anti-TNF-alpha treatment. We
hypothesize that the positive effects of ERT on these phenotypes
were likely due to soft tissue changes in the joints, rather than
direct delivery of the enzyme to the cartilage or bone. Since the
MPS VI rats do not exhibit markedly enlarged livers and spleens,
the improved motor activity and gait following ERT also cannot
be attributed to reduced organ size, although clearly this is a
positive benefit in MPS patients treated by ERT.
Importantly, the additive benefits of combined ERT/
CTNO1018 treatment on these clinical endpoints were signif-
icant, and occurred despite the fact that the reduction of serum
TNF-alpha and RANKL in both treatment groups were similar.
Indeed, we observed several changes in the cartilage of the
Figure 1. Anti-inflammatory effects of ERT and combined ERT/anti-TNF-alpha therapy in MPS VI rats. (A) MPS VI rats were subjected to
the ERT (black) or combined ERT/anti-TNF-alpha (gray) treatment for 8 months, as described in the text (n=8/group). The animals were euthanized 2
days after the last injection and serum was collected. Age-matched (37 weeks) normal (light gray) and untreated MPS VI (white) sera also were
collected, and TNF-alpha and RANKL levels were determined using immunoassay kits (see Materials and Methods). As previously shown, untreated
MPS VI animals had markedly elevated levels of these two inflammatory markers, and both were significantly reduced by either ERT or combined
treatment (*p,0.005). No significant differences were observed between the two treatment protocols. (B) Untreated MPS VI rats exhibited markedly
elevated TNF-alpha immunostaining (red) in the articular cartilage as compared to normal animals, which was modestly reduced by ERT and
normalized by combined treatment. (C) Hyperplastic synovial membranes (*) with the formation of villi (SV), and invasion of the synovium into the
subchondral bone (arrowhead, SB) was evident in untreated MPS VI and ERT-treated synovium. Animals treated with combined therapy exhibited
markedly less joint inflammation, although the storage cells were still present.
doi:10.1371/journal.pone.0022447.g001
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the ERT group. For example, the tracheas of MPS VI rats
receiving combined therapy were significantly thinner and wider
than untreated or ERT-treated animals, and collagen IIA1
expression was elevated in the articular collagen. Ceramide also
was reduced in the tracheas, indicative of reduced inflammation,
and PARP expression (indicative of apoptosis) was reduced in
articular chondrocytes. In addition, inflammation of the
synovium was markedly reduced by the combined therapy,
resulting in fewer villi and less invasion of the synovial tissue into
the underlying bone. Whether these changes were due to a direct
effect of CTNO1018 on these tissues, or an indirect effect
Figure 2. Motor activity and gait analysis in untreated and treated MPS VI rats. (A) MPS VI rats were subjected to ERT (boxes) or combined
ERT/anti-TNF-alpha (circles) treatment for 8 months, as described in the text (n=8/group). Two days after the last injection they were subjected to
accelerating rotarod analysis at three different speeds, and their performance was compared to untreated, age and gender-matched MPS VI animals
(triangles). At 10 RPM both groups of treated rats remained on the rotating rod for the maximal time (180 seconds), significantly longer than
untreated animals (p,0.005). This trend became more pronounced at higher speeds, and there was also a significant distinction between the ERT
and combined groups (p*,0.005). The times for individual animals are plotted, and the mean value for each group is indicated by the horizontal
lines. (B) After treatment the animals also were subjected to gait analysis, as described in the Materials and Methods. Two different colors of food
coloring were used to mark the front and hind paws of rats walking through a tube, and the distances between steps and angles of the steps were
measured from the paw prints. Each rat was tested at least three times, and a summary of the average paw print values are shown in this figure. As
can be seen, the angle of rear paw movement was reduced from 60u (untreated) to 45u (compared to untreated p=0.004) and 30u (compared to
untreated p=0.0001) for the ERT and combined treatment animals, respectively. In addition, the distance the animals could move their front paws in
each step was increased from 2.8 cm (untreated) to 4.2 cm and significantly to 5.1 cm in the combined treatment group (p=0.03). The distance the
animals moved their rear paws were not changed in the ERT group, and only modestly increased in the combined group (from 4.9 to 5.1 cm).
doi:10.1371/journal.pone.0022447.g002
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unknown. The effects on tracheal morphology were particularly
notable, suggesting that the respiratory complications associated
with the tracheal pathology in MPS patients may benefit from
the positive effects of combined ERT/anti-TNF-alpha therapy
[23,32].
Figure 3. Bone length and microarchitecture in untreated and treated MPS VI rats. (A) MPS VI rats were subjected to the ERT (black) or
combined ERT/anti-TNF-alpha (gray) treatment for 8 months, as described in the text (n=8/group). The animals were euthanized 2 days after the last
injection, and the femora and tibia were collected for microCT analysis. The results were compared to untreated age and gender-matched MPS VI rats
(white), and the values expressed as a percentage of normal controls. ERT did not increase the length of the femora or tibia, while the combined
protocol led to increases of ,6 and 14%, respectively. Of note, the tibia and femora in the combined treatment group were on average ,88 and 84%
of normal, compared to 74 and 77% in the untreated MPS VI group. (B) microCT analysis of the coronal views. In untreated and treated MPS VI rats
the trabecular density within the metaphyseal bone was reduced, the physeal growth plate was dysmorphic and disrupted, and the epiphyseal
trabeculae were disorganized relative to the normal femora. Mild improvement from the combined treatment was detected. (C) microCT analysis of
the mid-diaphyseal region of the femora showing axial views with subcortical trabecular infiltration into the marrow space. Although some
reductions in trabecular infiltration were noted following treatment, these could not be confirmed by quantitative measures.
doi:10.1371/journal.pone.0022447.g003
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treated MPS VI animals, there were few effects evident in the
bones. Femora and tibia lengths were mildly improved by the
combined treatment, but the growth plate histology was not.
These changes in bone length were very modest compared to
those previously observed in MPSVII/TLR4 double knockout
animals [18], where a clear improvement in the growth plate
organization was evident along with significantly longer bones.
However, several important differences between the two experi-
ments should be recognized, including different rodent models and
diseases, and the fact that in the MPS VII mouse study we created
a complete knockout of the TLR4 pathway that was exhibited
throughout development, while in the current study the rats were
subjected to treatment with a systemic anti-TNF-alpha therapy
beginning at ,3 weeks.
Overall, these results suggest that combining anti-TNF-alpha
therapy with ERT provided additional benefits in the cartilage and
bone of MPS animals, resulting in better clinical outcomes. Due to
the limited availability of CNT01081 we did not include a group
of MPS VI rats that were treated with this drug alone. Therefore,
we cannot rule out the possibility that some of the positive benefits
we observed were due to the anti-TNF-alpha therapy, rather than
combined treatment. However, since anti-TNF-alpha therapy
does not result in GAG reduction, it will almost certainly be used
in combination with ERT in MPS patients, making the effects in
the combined treatment group the most clinically relevant.
Implementation of this therapy in MPS patients may be
facilitated by the fact that several anti-TNF-alpha drugs are
available for clinical use in other inflammatory conditions (e.g.,
RemicadeH, etc). However, chronic use of these therapies in MPS
patients also may have deleterious effects, and carefully controlled
clinical trials will be necessary to determine the safety and efficacy
of this combined treatment protocol. A second important finding is
that ERT alone reduces TNF-alpha related inflammation,
providing additional evidence that GAG storage in the MPS
diseases is directly activating this pathway. Indeed, the general
Figure 4. Tracheal defects in untreated and treated MPS VI rats. (A) Tracheas were collected from treated and untreated MPS VI and normal
animals at the end of the study (37 weeks of age). As illustrated by this representative figure, untreated MPS VI rats had markedly thickened and
abnormal, collapsed tracheas with narrow, flattened interior openings. These abnormalities were not altered by ERT, but were clearly improved by the
combined treatment which resulted in rounded tracheas with almost statistically normalized cross sectional areas. (B) Immunohistochemical analysis
of the tracheas showed increased expression of the pro-inflammatory and pro-apoptotic sphingolipid, ceramide, in the epithelial cells of untreated
and ERT-treated animals (red), consistent with the occurrence of inflammatory disease. Tracheas from the combined treatment group showed almost
normal ceramide expression.
doi:10.1371/journal.pone.0022447.g004
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secondary benefits to organs that the enzyme cannot reach.
Lastly, the data reported here further validates the fact that TNF-
alpha, RANKL and other inflammatory markers can be used as
biomarkers to monitor the effects of therapies in the MPS diseases.
Currently, the only biomarker that is widely used in these disorders
is GAG release in the urine, and these simple serum assays may
have considerable, additive benefits.
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